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Hemolytic uremic syndrome is deﬁned by the characteristic triad of microangiopathic hemolytic anemia, thrombocytopenia,
and acute renal failure. In children, most cases of HUS are caused by Shiga-toxin-producing bacteria, especially Escherichia coli
O157:H7. Common vehicles of transmission include ground beef, unpasteurized milk, and municipal or swimming water. Shiga-
toxin-associated HUS is a main cause of acute renal failure in young children. Management remains supportive as there is at
present no speciﬁc therapy to ameliorate the prognosis. Immediate outcome is most often favourable but long-term renal sequelae
are frequent due to nephron loss. Atypical HUS represents 5% of cases. In the past 15 years, mutations in complement regulators
of the alternative pathway have been identiﬁed in almost 60% of cases, leading to excessive complement activation. The disease
has a relapsing course and more than half of the patients either die or progress to end-stage renal failure. Recurrence after renal
transplantation is frequent.
1.Introduction
The hemolytic-uremic syndrome (HUS) is deﬁned by the
association of hemolytic anemia (low haptoglobin levels,
high lactate deshydrogenase levels, and schistocytes), throm-
bocytopenia, and acute renal failure [1]. It is a common
cause of acute renal failure in patients younger than three
years who require acute dialysis. The renal histological
lesion is glomerular thrombotic microangiopathy and in
more severe cases, arteriolar thrombotic microangiopathy.
Increased platelet aggregation and thrombi aﬀect the micro-
circulation. Thrombotic microangiopathy may aﬀect other
organ systems, including the central nervous system [2].
HUS can be divided into two forms, typical and atypical
HUS. Typical D+ or shiga-toxin associated HUS is the most
common form of HUS in children accounting for 90 percent
of all cases. It usually occurs after a prodromal episode of
diarrhea that is frequently bloody. In the majority of cases,
HUS is associated Shiga toxin-producing enterohemorrhagic
Escherichia coli (EHEC) or Shigella [3–7] and generally
carries a good prognosis [6]. Atypical HUS (aHUS) is a
heterogeneous disorder which is responsible for only 10
percent of cases in children [8, 9]. It is also referred to
as nondiarrhea-associated HUS, D-HUS, or sporadic HUS.
In addition to the usual absence of a diarrheal prodrome,
children with aHUS may have an insidious onset, a relapsing
course, or a progressive course leading to severe renal
dysfunction [1, 8, 10]. Blood pressure is often markedly
increased. There is a high risk of recurrence after renal
transplantation.
2.Shiga-Toxin-(Stx-)AssociatedHUS
In the majority of cases, Stx-HUS is triggered by strains of
EHEC that produce a Shiga toxin [3, 7, 11], but Shigella
dysenteriae can also be involved [4, 12]. It usually occurs
after a prodromal episode of diarrhea that is frequently
bloody in nature. Five to 10 days after onset, HUS devel-
ops abruptly [13, 14]. Cases of HUS in children due to
Shiga toxin-producing E. coli infections other than colitis
(e.g., urinary tract infections) can occur [15]. Although
these cases are not associated with diarrhea, the clini-
cal course and pathophysiology are the same as the D+
HUS.2 International Journal of Nephrology
2.1. Epidemiology. Stx-HUS principally aﬀects young chil-
dren. The annual incidence of the disease in North America
and Western Europe is about 2 to 3 per 100,000 children
less than ﬁve years of age [6, 12]. Stx-HUS occurs most
commonly in the summer months [11] and is more frequent
in rural versus urban populations [7]. Most cases are
sporadic, but outbreaks are often reported due to a common
contaminated food or water source. The natural reservoir
of EHEC is the digestive tract of healthy cattles Infection
in humans occurs following ingestion of contaminated
undercooked meat, unpasteurized milk or milk products,
water, fruits, or vegetables [16]. Secondary human-to-
human transmission is also a major risk factor for HUS
[14, 17] and may be a concern in day-care centers or in
sibships.
EHEC causes at least 70 percent of cases of postdiarrheal
HUS in the United States, 80 percent of which are caused
by E. coli O157:H7, but non-O157 strains are also involved.
Although laboratory diagnosis of EHEC infection [18]c a n
be made by stool culture, the bacteria are only present in
the stools for a few days and, even if present, may not be
detected by culture from stool samples. The rate of stool
isolation is substantially higher in the ﬁrst six days after
onset of diarrhea. Direct detection of shigatoxin in stool is
anotherdiagnostictool.Only10–15%ofchildrenwithE.coli
O157 colitis eventually develop HUS [19] suggesting that, in
addition to pathogen factors, host factors also contribute to
its development. Shigella dysenteriae type 1-associated HUS
occurs in India, Bangladesh, and southern Africa. Although
the pathogenesis of disease is similar to that of HUS induced
by O157 E. coli infection, the disease is usually more severe
withanacutemortalityrateof15percentandover40percent
of patients developing chronic renal failure [12].
E. coli infection has become a major health care concern.
Prevention recommendation should be provided to patients
and their parents including meticulous hygiene when cook-
ing and changing diapers, avoidance of undercooked meat
and unpasteurized milk products in young children. Cattle
vaccination could also help reducing the reservoir of E. coli.
Promising results have been obtained in reducing the fecal
shedding of E. coli O157:H7 and hide contamination fol-
lowingcattlevaccination[20–22].Butlargerepidemiological
studies are needed to assess a potential beneﬁcial eﬀect of
cattle vaccination for food and environmental safety.
2.2. Pathophysiology. Shiga toxin-(Stx-) mediated injury to
vascular endothelial cells in the kidney, brain, and other
organs underlies the pathogenesis of HUS caused by EHEC.
These potent cytotoxins are released in the gut by bacte-
ria, enter the blood stream, and cause endothelial injury
through the binding to the globotriaosylceramide (Gb3)
receptor on the plasma membrane of target cells [23].
Gb3 is a sphingolipid receptor expressed on endothelial
cells, podocytes, and proximal tubular cells in human. Stx
binding to Gb3 leads to Stx internalization by receptor-
mediated endocytosis and its retrograde transport to the
endoplasmic reticulum. This triggers a cascade of signalling
events, involving NF-κB activation, which induces apoptosis
and the binding of leukocytes to endothelial cells [24].
Stx-activated endothelial cells become thrombogenic by a
complex mechanism not yet fully unravelled [24]. It has
been demonstrated that Stxs modulate the expression of
endothelial cell adhesive molecules such as β3-integrin
subunit, vitronectin receptor, PECAM-1, and P-selectin
on the microvasculature [25] and induce the release of
cytokines and chemokines by endothelial cells, implicated
in platelet activation [26]. Moreover, upon Stx activation,
endothelial Von Willebrandt factor has been shown to
undergo conformational changes thereby mediating platelet
adhesion on activated endothelial cells [25]. Additionally,
Stxs stimulate in vitro the release of unusually large Von
Willebrandt factor strings and impair their cleavage by
the metalloprotease ADAMTS-13 [27]. Altogether, these
endothelial cell dysfunctions associated to platelet activation
may promote platelet adhesion on glomerular endothelial
cells, thrombi formation, and glomerular occlusion in Stx-
HUS. An in vitro study showed that in addition to directly
damaging the kidney, Stxs also activate complement and
delay the function of its inhibitor, factor H, on the cell
surface, leading to indirect kidney damage [28].
Stxs include two major antigenic forms (Stx1 and Stx2)
with diﬀerent subtypes which diﬀer in potency. Stx2a and
Stx2d have been reported as the most potent [29]. Stx type-
speciﬁc mechanisms of endothelial cell injury have been
suggested in cellular models [30]. Bauwens et al. demon-
strated that Stx1 causes both necrosis and apoptosis, whereas
Stx2 induces almost exclusively apoptosis in human brain
microvascular endothelial cell lines and inmacrovascular
endothelial cells [30]. Free toxins have never been detected
in the blood of HUS patients, but they have been found on
the surface of polymorphonuclear leukocytes [31]. Puriﬁed
Stxs alone are capable of producing HUS with glomerular
thrombotic microangiopathy in large animal models such as
baboons [32]. Conversely, rodents develop tubular lesions
but no glomerular damage after Stx injection. This may be
related to Gb3 expression diﬀerences among species. Indeed,
Gb3 expressed on tubular cells is absent from glomerular
endothelial cells and podocytes in mice [23]. Similarly, cattle
which are the main vectors of EHEC lack Gb3 expression
in their glomeruli. This may partly explain why they do
not develop HUS [33]. This led to the hypothesis that
diﬀerent patterns of Gb3 expression with age could explain
the predominance of HUS among young children. However,
it was shown that Gb3 expression in the kidney and Stx1
binding to kidney structures does not vary with age [34].
Factors other than basal renal Gb3 expression, yet to be
identiﬁed, account for the age-related incidence of Stx-HUS
in EHEC infection. The increased frequency of antibodies to
Stx1 and Stx2 suggests that preexisting immunity may play a
role in age-speciﬁc host resistance to HUS [35].
2.3. Clinical Manifestations. Stx-producing E. coli causes a
spectrum of outcomes ranging from asymptomatic carriage
to diarrhea that may be uncomplicated or bloody to HUS.
The diarrhea and associated gastrointestinal complaints in
the prodromal phase of Stx-HUS may mimic those of
ulcerative colitis, other enteric infections, and appendicitis.
HUS is deﬁned by the sudden onset of microangiopathicInternational Journal of Nephrology 3
hemolytic anemia with fragmented erythrocytes named
schistocytes and negative Coombs’ tests, thrombocytopenia,
and acute kidney injury [11]. Despite the thrombocytopenia,
there is usually no purpura or active bleeding. Whereas
the degree of anemia or thrombocytopenia is unrelated to
the severity of renal dysfunction, an increased white blood
cell count is associated with a worse prognosis [36]. The
hematologic manifestations of Stx HUS completely resolve
usually within one to two weeks.
The renal involvement ranges from hematuria usually
microscopic and proteinuria, to severe renal failure and
oliguria that occur in one-half of cases. Hypertension is
common. Dialysis is instituted to correct metabolic abnor-
malities when required. The short-term renal prognosis
is generally favourable. However, the risk of renal failure
20 years after the recovery of Stx-HUS is not negligible,
and renal histology showing a glomerular microangiopathy
aﬀecting >50 percent of glomeruli, arterial microangiopathy,
and/or cortical necrosis is the best indicator of long-term
prognosis [37, 38].
Stx-HUS commonly aﬀects other organ systems [36].
Central nervous system involvement occurring in 20–50
percent of children with Stx-HUS is the most threatening
complication associated with increased morbidity and mor-
tality [2, 39, 40]. Patients may present with seizures, coma,
stroke,hemiparesis,facialpalsy,pyramidalorextrapyramidal
syndromes, dysphasia, diplopia and cortical blindness [39].
Brain MRI typically reveals bilateral hypersignal on T2-
weighted and hyposignal on T1-weighted images of basal
ganglia, thalami, and brainstem sometimes extending to
the surrounding white matter [41]. Additionally, MRI may
display images of high blood pressure complications such
as reversible posterior leukoencephalopathy syndrome and
cerebral hemorrhage. In a large French multicenter series
of 52 children with Stx-HUS and neurological involvement,
nine patients died, 17 had mild to severe sequelae, and 26
fully recovered [2].
The whole digestive tract can also be involved. The more
serious manifestations include severe hemorrhagic colitis,
bowel necrosis and perforation, rectal prolapse, peritonitis,
and intussusception [42]. Cardiac ischemia and dysfunction
may occur. Transient and rarely permanent diabetes mellitus
may occur [42]. Hepatomegaly and/or increased serum
transaminases are frequently observed. The mortality rate
has dropped to about 5%, usually due to neurologic or
cardiac involvement [43]. Persistent oliguria (>5d a y so f
anuria and >10 days of oliguria), dehydration, elevated white
blood cells > 20,000 per mm3, and hematocrit > 23 percent
are risk factors for death [43] and long-term complications
from HUS [44].
2.4.Therapy. OnceapatientisinfectedwithEHEC,attempts
to prevent progression from the bloody diarrheal phase to
the postdiarrheal phase of HUS have been unsuccessful.
Antimotility drugs (such as anticholinergic agents and
narcotics) do not reduce the progression to HUS due to
EHEC infections, but in fact appear to increase the risk of
subsequent development of HUS. In patients with EHEC,
both retrospective and prospective observational studies
report an increased risk of HUS with the administration of
antibiotics during the bloody diarrheal phase [45]. In one
retrospective review of 278 children with HUS, the use of
antimotility drugs (anticholinergic agents and narcotics) was
associated with an increased risk of subsequent development
of HUS (OR 2.9, 95% CI 1.2 to 7.5) [46]. In another ret-
rospective study of 91 patients, antimotility drugs increased
the risk of central nervous system dysfunction (OR 8.5, 95%
CI 1.7 to 42.8) [40]. Based upon these data, antibiotics
and antimotility drugs should not be given to a child with
conﬁrmed or suspected E. coli O157:H7 infection. Increased
volume expansion with intravenous isotonic saline during
the diarrheal phase has been reported to attenuate but not
prevent renal injury [6, 47].
Treatment of Stx-HUS includes supportive measures
such as management of anemia, signiﬁcant clinical bleeding,
ﬂuid and electrolyte disturbances, hypertension, and other
extrarenal complications, together with renal replacement
therapy required in 30–60% of cases [48]. Additionally,
multiple modalities and/or agents have been utilized that
are directed against the underlying or presumed pathogenic
mechanisms of Stx-HUS. These include antithrombotic
agents, plasma exchange and/or plasma infusion, tissue-
type plasminogen activator, and oral Shiga toxin-binding
agent. Although none of these agents have been shown to
be eﬃcacious, there may be a role for plasma exchange in
patients with severe CNS involvement. The remaining agents
which have not proven eﬃcient are not recommended. Stx-
receptor (Gb3) mimics and Stx-neutralizing (monoclonal)
antibodies (STmAb) may be more promising. Although
the ﬁrst-generation Gb3-analog failed to ameliorate the
disease course in a randomized placebo-controlled trial [49],
advanced Stx receptor analogs and polymers, and peptide-
based intracellular toxin inhibitors have been developed
and could have more beneﬁcial eﬀects in the future [50–
52]. STmAb injection 24h after oro-gastric inoculation of
Stx2-producing bacteria prolonged the survival of toxin-
challenged mice [53]. This provided the rationale for the use
of STmAb products for Phase 1 studies in patients in which a
satisfactory tolerability was demonstrated [54]. Randomized
controlled trials are needed to conﬁrm the potential role
of STmAb in patients with Stx-HUS. Eculizumab looks
promising in severe cases with neurological involvement
refractory to plasma therapy [55]. Finally, treatments target-
ing downstream events in the inﬂammatory or proapoptotic
cascade induced by Stx could be a good option, yet to be
developed.
3.AtypicalHUS
An increasing number of genetic causes of aHUS have
been described [1]. These include aHUS associated with
mutation of genes encoding for regulators of the alternative
complement pathway, Von Willebrand factor cleaving pro-
tease (ADAMTS13) deﬁciency, and intracellular defects of
vitamin B12 metabolism. There are also cases of unknown
etiology that are associated with an autosomal recessive and
autosomal dominant inheritance.4 International Journal of Nephrology
3.1. Atypical HUS and Defective Complement Regulation.
Mutations in the genes encoding complement proteins
including C3, factors H, B, and I, and membrane cofactor
protein (MCP) are associated with atypical HUS [56, 57]. It
is estimated that approximately 60 percent of cases of aHUS
result from mutations in these genes [56]. These mutations
result in dysregulation of the complement system that
leads to excessive complement activation and in endothelial
damage.
The gene that is aﬀected determines the clinical presen-
tation and outcome [58, 59]. For example, patients with
mutations of the gene for factor H (CFH)o f t e np r o g r e s s
to ESRD within the ﬁrst year of presentation. By contrast,
only few patients with MCP mutations progress to ESRD,
although relapse is common [59]. Interestingly, only 50% of
individuals with CFH or CFI or MCP mutation eventually
develop aHUS, which mean that additional risk factors
are involved in the development of the disease. Combined
mutations of the genes encoding complement proteins are
observedin5%ofpatients.TheassociationofCFH andMCP
haplotypes with aHUS has been reported [60].
3.1.1. Factor H Mutations. The association between aHUS
andmutationsinCFH wasﬁrstdescribedbyWarwickeretal.
[61]. It was subsequently found that it is the most frequent
genetic abnormality in patients with aHUS, accounting for
25 to 30% of cases [62–65]. Most mutations are heterozy-
gous. Factor H, a serum complement regulatory protease,
acts as a cofactor for factor I-mediated inactivation of C3b,
competes with factor B for C3b binding, and accelerates
C3 convertase decay. More than 70 mutations have been
reported. Most mutations aﬀect the short consensus repeats
19 and 20 of the protein. Most of them are missense
mutations, which do not aﬀect the levels of factor H and
C3 but aﬀect the C-terminal region, which is important
for binding to C3b and anionic surfaces [66, 67]. Other
mutationsarelocatedthroughoutthegeneandareassociated
with low levels of factor H antigen. Interestingly, renal
survival is higher in patients with low factor H levels
compared with those with normal levels of factor H. Patients
with homozygous mutations have very low levels of factor
H antigen, low C3, low factor B, and low CH50. aHUS
associated with factor H mutations may present during
infancy or early childhood, or in adulthood [62, 63, 68–
71]. The disease may be sporadic or clearly associated with
a family history of disease. Hemolytic anemia is marked at
disease onset and during relapses, with haptoglobin levels
remaininglowduringthecourseofthedisease.Hypertension
is frequently severe. Progression to end-stage renal disease is
often rapid, and there is a very high risk of recurrence after
renal transplantation (75 to 90%) [72, 73].
3.1.2. Mutations in MCP (Membrane Cofactor Protein).
Mutations in the complement regulatory protein MCP are
observed in 5 to 10% of aHUS [58, 74–76]. MCP is the
cofactor of factor I for the degradation of C3b and C4b.
The mutation results either in a reduction of cell surface
levels of MCP (most common) or an impaired function
of MCP [75]. The disease is characterized by onset in
childhood, a favourable renal outcome in most patients,
frequent relapses and a low rate of recurrence in the renal
allograft.
3.1.3. Factor I Mutations. Factor I is a serine protease which
cleaves C3b and C4b in the presence of factor H and MCP.
The frequency of CFI mutations in patients with aHUS
varies between 3 and 10% [77]. Up to 15 diﬀerent mutations
have been identiﬁed [78]. Most patients have heterozygous
mutations [79]. They result in either a quantitative defect
or a qualitative defect of the protein. HUS often occur in
early childhood, and progression to end-stage renal disease
is observed in more than 50% of cases [80]. Other genetic
anomalies are frequent and may explain a worse outcome in
some patients. Recurrence occurs in 45 to 80% of patients,
resulting in graft loss.
3.1.4. C3 Mutations. Heterozygous C3 mutations have been
identiﬁed in patients with aHUS [81]. Fremeaux-Bacchi et
al. reported 9 novel mutations in 14 patients with aHUS and
persistently low serum C3 levels. Five of the seven C3 mutant
proteins showed a reduced binding to MCP, possibly leading
to a gain of function relative to complement activation.
The mean age at presentation was 6.5 years (range 8
months to 40 years). Seven of the 14 patients regained
function after their initial presentation and four of these
patients had recurrent disease. Among the 14 patients, there
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aHUS [82, 83]. Progression to end-stage renal disease occurs
in70%ofpatientsandallfourrenaltransplantationreported
failed because of HUS recurrence.
3.1.6. Thrombomodulin Mutations. Thrombomodulin is a
cofactor in the initiation of the protein C anticoagulant
pathway. In addition, it was shown that thrombomodulin
accelerates the inactivation of C3b by factor I. In a study
of 152 patients with atypical HUS, seven patients had six
diﬀerent heterozygous mutations of the THBD gene, which
encodes thrombomodulin [84]. In vitro studies demon-
strated that these mutations resulted in a decreased capacity
to inactivate C3b, which may lead to excessive complement
activation.
3.1.7.AntifactorHAutoantibody-AssociatedaHUS. Thepres-
ence of autoantibodies against factor H is observed in 6
to 10% of cases, mainly in children, between 9 and 12
years. These antibodies interfere with the binding of factor
H to the C3 convertase and are associated with a defective
factor H-dependent cell protection [85, 86]. Most patients
have a homozygous deletion of CFHR1 and CFHR3 genes
[87–89]. The clinical course is characterized by a high
frequency of relapses. Progression to end-stage renal disease
is observed in 20 to 35% of cases [90]. Plasma exchange plus
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in some patients with factor H antibodies [91]. Recurrence is
observed when the autoantibodies are still present at time of
transplantation [92].
3.1.8. Treatment. Intensive plasma exchange (40 to
60mL/kg) is the ﬁrst-line therapy for patients during
the acute episode of aHUS. The response to plasma
treatment appears to vary depending upon the aﬀected
complement component [58, 93]. In patients with either
factor H or factor I deﬁciencies, about two-thirds of patients
willremitwithplasmatherapy.Incontrast,therehasbeenno
diﬀerence in remission rates with or without plasma therapy
in patients with MCP deﬁciency. Patients with antifactor
H autoantibodies should receive an immunosuppressive
treatment in addition to plasma exchanges.
Eculizumab is a monoclonal antibody which binds to C5
and prevents the generation of C5a and the formation of
the membrane attack complex. Eculizumab has been used
in patients with aHUS on native kidney or recurrence of
aHUS after transplantation with very encouraging results
[94–97]. A prolonged therapy is more eﬀective than a single
dose. The delay between two injections should not exceed
14 days. The duration of therapy is still a matter of debate.
A multicenter trial in children to establish the eﬃcacy and
safety of eculizumab in aHUS is ongoing.
Patients with mutations in genes for factor H, factor I,
or C3 who fail to respond to plasma therapy and/or have
recurrent disease are likely to progress to ESRD [98]. It
is unclear whether renal transplantation is an appropriate
intervention in these patients, because recurrence of disease
occurs in 50 percent of the transplanted kidney, and graft
failure occurs in 90 percent of those with recurrent disease
[72, 99]. Genotyping for complement protein genes should
be performed in patients who have atypical HUS and
end-stage renal failure and are being considered for renal
transplantation. Indeed, the risk of recurrence is dependent
on the type of mutation; such genotyping is particularly
important when living-related renal transplantation is being
considered, so that cases in which de novo HUS occurs in the
donorcanbeavoided.Mostcliniciansagreethatlivingdonor
renal transplantation is contraindicated in patients with
atypical HUS because of the high risk of disease recurrence
after transplantation [1].
In 2007, a consensus conference recommended a com-
bined liver-renal transplantation in aHUS cases in which
renal transplantation is extremely unlikely to succeed [100,
101]. This would include patients with factor H or I
deﬁciency who have lost an isolated kidney transplant due
to disease recurrence or have a family member with the
same gene mutation who lost a kidney transplant due to
disease recurrence. The transplantation should be preceded
by plasma exchange, and plasma should be infused intra-
operatively and continued until liver function is adequate.
Eculizumab is another option [94, 96].
3.1.9. Atypical HUS and Von Willebrand Factor Cleaving
Protease Deﬁciency. Von Willebrand factor (VWF), a glyco-
protein that carries factor VIII in the circulation, is required
for platelet adhesion and platelet aggregation [102]. Large
multimersofVWFaremoreeﬀectivethandimersforplatelet
adhesion and platelet aggregation. The large multimers do
not normally circulate because they are cleaved by a speciﬁc
protease, a metalloprotease synthesized by the liver. This
protease is the thirteenth member of the ADAMTS family,
or ADAMTS13.
Many cases of adult thrombotic thrombocytopenic pur-
pura (TTP) are due to deﬁcient activity of the VWF cleaving
protease. Protease deﬁciency may be inherited by autosomal-
recessive transmission or may be induced by an acquired
autoantibody that inhibits protease activity [103, 104]. A few
cases of antibody-induced VWF cleaving protease deﬁciency
have been reported in children aged 1 to 11 years who
p r e s e n t e dw i t hs y m p t o m so fT T P .
Most children with VWF-cleaving protease deﬁciency
related to mutations in the ADAMTS13 gene present at
birth with hemolytic anemia and thrombocytopenia. Renal
involvement often occurs later in life and has a progressive
course. Onset of disease up to ﬁve years of age has also been
reported. Many develop symptoms of CNS involvement.
3.1.10. Atipical HUS and Defects of Vitamin B12 Metabolism.
Vitamin B12 or cobalamin is the coenzyme of methionine-
synthase (or methyl-transferase), which transforms homo-
cysteine in methionine. It is also the coenzyme of
methylmalonyl-CoAmutase,whichisinvolvedintheconver-
sion of methylmalonyl CoA to succinyl-CoA [105]. Children
aﬀected with cobalamin C mutations have a functional
defect of both methylmalonyl CoA mutase and methionine-
synthase. This defect results in methylmalonic acidemia with
homocystinuria.
Approximately 25 percent of reported cases also have
atypical HUS [105]. The ﬁrst symptoms, which are nonspe-
ciﬁc, occur in the neonatal period and consist of anorexia,
vomiting, failure to thrive, hypotonia, seizures, and lethargy
[106, 107] .T h eﬁ r s ts ym p t o m so fH U Sa r eo b s e rv e db e t w e e n
the end of the ﬁrst month and three months of age
with severe hemolytic anemia with schistocytes, which is
accompanied by macrocytosis, frequent thrombocytopenia,
hematuria, proteinuria, renal dysfunction of variable sever-
ity, and hypertension.
Amino acid and organic acid chromatography reveal
a marked increase of homocysteine and a low level of
methionine in the plasma, while urinary excretion of homo-
cysteine and methylmalonic acid is very high. Therapy with
hydroxycobalamin should be started as soon as possible
[107].
3.2. Other Causes of Atypical HUS. HUS may occur during
treatments with cytotoxic drugs, such as mitomycin C,
bleomycin, or cisplatin [108, 109]. HUS has been described
in patients with HIV infection [110, 111]. HUS has been
observed in patients with systemic lupus erythematosus
[112]aswellasinthosewithacatastrophicantiphospholipid
syndrome.
3.3. HUS after Renal Transplantation. HUS may be observed
following renal transplantation either as a recurrent or a de
novo disease [113]. More than 50% of patients with aHUS6 International Journal of Nephrology
have mutations in genes coding for regulatory factors of the
complement system or antibodies against factor H. The risk
of recurrence depends on the genetic defect. When the risk
of recurrence is high, as in patients with mutations in genes
coding for circulating regulators of complement, isolated
renaltransplantationiscontraindicatedgiventhehighriskof
recurrence, although the use of eculizumab may allow such
procedure.
Drug-induced HUS has been observed in transplant
patients treated with either cyclosporine or tacrolimus [114,
115]. It usually occurs during the ﬁrst few months posttrans-
plantation, a time when high doses of calcineurin inhibitors
are being administered.
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